Loading…

AlvotechALVOCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops and manufactures biosimilar versions of major biologic drugs for global markets.

Momentum leader 80
Mkt cap
$1.62B
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$4.93M
20-day average traded
Fwd P/E
22.6×
forward earnings
ROIC−WACC
-2.5 pp
WACC 6.1%
Hurdle
n/a
no reverse DCF
Next earnings
112 days
10 Mar 2027
Close · USD$4.55
1D+4.1%
1W-7.5%
1M-11.1%
3M+6.6%
6M+37.9%
YTD-11.3%
1Y-11.5%
ATR %6.9%
Beta0.86
52w lowhigh30.3% off high

What Alvotech does

Develops and manufactures biosimilar versions of major biologic drugs for global markets.

Sells through marketing partners in each region instead of building its own sales force: it supplies the drug and shares in the sales, and also receives milestone payments when products are approved or launched. Its manufacturing is based in Reykjavik, Iceland. Founded by Robert Wessman, linked to Alvogen.

Products and services

  • Biosimilar to Humira (AVT02)
  • Biosimilars to Eylea and Stelara

Customers

  • Pharma distribution partners (Teva, STADA)
  • Health systems/payers globally

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Biosimilar drug development and…

What could go right

  • Biologic patent cliff creating biosimilar opportunities
  • US interchangeability designations

What could go wrong

  • Biosimilar pricing competition
  • Regulatory and manufacturing compliance risk

Moat: narrow (regulatory licence, scale, process know-how). In-house biosimilar manufacturing at scale, but competes on price against multiple approved biosimilars.

Headquarters: Reykjavik, Iceland · Founded: 2013 · Employees: 1,460

Named competitors

Alvotech at a glance

Size Alvotech (ALVO) is a United States Health Care company (Biotechnology) with a market value of $1.62B, the 1909th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.55 on 18 Nov 2026.

Performance Over six months the shares gained 37.9%, against -11.9% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue fell 14.2% over the last twelve months (peer median +24.9%); the operating margin is 11.5% (peer median 3.4%).

Valuation It trades at 22.6× forward earnings against a peer median of 37.0× (4th cheapest of 9).

Capital Return on invested capital runs 2.5 points below its cost of capital (6.1% WACC).

Short interest Short interest is 1.6% of the free float (30 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026ALVO 135Peer median 90
Six months, rebased to 100: Alvotech against the median of its 20 peers (local-currency closes).

Alvotech financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$490M$586M$490M$91.4M$83.0M
Revenue growth—+20%+436%+10%—
Gross profit$278M$335M$292M-$78.0M$8.58M
EBITDA$98.7M$113M$98.6M-$331M-$325M
Net income-$249M$27.9M-$232M-$552M-$514M
Free cash flow-$318M-$115M-$291M-$345M-$350M
Capital expenditure$144M$96.1M$57.0M$46.5M$49.0M
Total debt$1.56B$1.45B$1.19B$1.08B$805M

Quarterly statements and history in the cockpit →

Alvotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%688222ANIP6949600226PPGNVIR145020NRIXPGENKLRAKRSASTOKRXRX087010688046ZBIO2637ALVO6-month return →1-month return →
Up and to the right = strong over both horizons. Alvotech is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%20×40×60×688222ANIP600226PPGN145020PGEN6880462637ALVORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alvotech is the large dot.

Alvotech competitors and peer comparison

Head to head with its named competitors (ALVO vs SDZ.SW vs 068270.KS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Alvotech ALVO$1.62B+38%-14%12%22.6×n/a
Sandoz SDZ.SW$41.7B+26%+1%15%24.5×7.5%
Celltrion 068270.KS$34.9B+12%+40%32%33.9×10.6%

How Alvotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alvotech against its 20 peers (data as of 18 Nov 2026)
MeasureALVOPeer medianRank in peer set
1-month return-11.1%-7.1%8th lowest of 21
6-month return+37.9%-11.9%3rd highest of 20
Distance from 52-week high-30.3%-44.5%4th highest of 21
Revenue growth (TTM)-14.2%+24.9%4th lowest of 19
Operating margin11.5%3.4%8th highest of 19
Forward P/E22.6×37.0×4th cheapest of 9
ROIC minus cost of capital-2.5 pp-5.9 pp7th highest of 15
EV / EBITDA31.6×8.5×2nd most expensive of 6
Net debt / EBITDA15.2×-1.1×most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Alvotech ALVOUnited States$1.62B+38%-14%12%22.6×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%73.2×33.2%+16.8%
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%7.5×-7.6%+33.5%
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%n/an/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%27.6×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%52.1×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%n/an/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%18.1×-12.1%+15.0%
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%n/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%7.3×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%n/an/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%n/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%n/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%51.9×33.0%+24.8%
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%n/an/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a

Questions

Who are Alvotech's main competitors?
Named competitors: Sandoz (SDZ.SW), Celltrion (068270.KS), Coherus BioSciences (private or unlisted). The cockpit's measured peer set (industry) also includes Hitgen (688222.SS), ANI Pharmaceuticals (ANIP), PELL Bio-Med Technology (6949.TW), Zhejiang Hengtong (600226.SS), PolyPeptide (PPGN.SW), Vir Biotechnology (VIR).
Is Alvotech expensive compared with its peers?
On forward p/e it trades at 22.6× against a peer median of 37.0×, 4th cheapest of 9 in its peer set.
How has Alvotech stock performed?
Over six months to 18 Nov 2026 the shares returned +37.9% against -11.9% for the median peer; over one year -11.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.